Qiagen NV
QGEN47.110USD
-0.280-0.59%
Fechamento 06/13, 16:00（ET）Cotações atrasadas em 15 min
10.20BValor de mercado
122.05P/L TTM
Mais detalhes de Qiagen NV Empresa
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Informações da empresa
Código da empresaQGEN
Nome da EmpresaQiagen NV
Data de listagemSep 01, 1996
Fundado em1996
CEOMr. Thierry Bernard
Número de funcionários5765
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 01
EndereçoHulsterweg 82
CidadeVENLO
Bolsa de valoresNYSE Consolidated
PaísNetherlands
Código postal5912 PL
Telefone31773556600
Sitehttps://www.qiagen.com/
Código da empresaQGEN
Data de listagemSep 01, 1996
Fundado em1996
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Mr. Stephen H. (Steve) Rusckowski
Mr. Stephen H. (Steve) Rusckowski
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
24.00
--
Ms. Eva van Pelt
Ms. Eva van Pelt
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Dr. Toralf Haag, Ph.D.
Dr. Toralf Haag, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Mr. Lawrence A. Rosen
Mr. Lawrence A. Rosen
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Roland Sackers
Mr. Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Board
Managing Director, Chief Financial Officer, Member of the Executive Board
383.09K
+59.93%
Mr. Thierry Bernard
Mr. Thierry Bernard
Chief Executive Officer, Managing Director, Member of the Executive Board
Chief Executive Officer, Managing Director, Member of the Executive Board
312.13K
+75.76%
Dr. Metin Colpan, Ph.D.
Dr. Metin Colpan, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
171.79K
-57.00%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
47.22K
+10.37%
Prof. Dr. Ross L. Levine, M.D.
Prof. Dr. Ross L. Levine, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
16.27K
+30.83%
Prof. Dr. Elaine R. Mardis, Ph.D.
Prof. Dr. Elaine R. Mardis, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
3.97K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Por EmpresaUSD
Nome
Receita
Proporção
Consumables and Related Revenues
1.76B
88.98%
Instrumentation
218.00M
11.02%
Por RegiãoUSD
Nome
Receita
Proporção
United States
942.01M
47.62%
Europe & Middle East & Africa
648.49M
32.78%
Asia, Pacific & Rest of the World
298.15M
15.07%
Other Americas
89.56M
4.53%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumables and Related Revenues
1.76B
88.98%
Instrumentation
218.00M
11.02%
Distribuição de ações
Atualizado em: sáb, 14 de jun
Atualizado em: sáb, 14 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Wellington Management Company, LLP
11.29%
MFS Investment Management
11.20%
BlackRock Institutional Trust Company, N.A.
9.64%
The Vanguard Group, Inc.
4.06%
Amundi Asset Management, SAS
1.94%
Other
61.87%
Investidores
Investidores
Proporção
Wellington Management Company, LLP
11.29%
MFS Investment Management
11.20%
BlackRock Institutional Trust Company, N.A.
9.64%
The Vanguard Group, Inc.
4.06%
Amundi Asset Management, SAS
1.94%
Other
61.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
46.01%
Investment Advisor
30.43%
Hedge Fund
3.22%
Research Firm
3.21%
Sovereign Wealth Fund
1.87%
Holding Company
1.17%
Bank and Trust
1.11%
Pension Fund
1.10%
Individual Investor
0.44%
Other
11.45%
Participação acionária institucional
Atualizado em: seg, 20 de jan
Atualizado em: seg, 20 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
987
158.50M
73.34%
-14.17M
2024Q4
1010
129.03M
59.70%
-70.06M
2024Q3
1010
183.22M
84.72%
-23.62M
2024Q2
1002
184.34M
84.75%
+8.40M
2024Q1
988
165.20M
76.61%
-7.18M
2023Q4
993
165.11M
76.72%
-10.52M
2023Q3
987
159.93M
74.32%
-12.21M
2023Q2
996
162.43M
75.49%
-6.05M
2023Q1
1001
160.07M
74.44%
-9.45M
2022Q4
1009
160.10M
74.55%
-10.38M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Wellington Management Company, LLP
23.29M
10.78%
+2.11M
+9.98%
Jan 31, 2025
BlackRock Institutional Trust Company, N.A.
19.32M
8.94%
-13.86K
-0.07%
Mar 04, 2025
The Vanguard Group, Inc.
8.54M
3.95%
+77.90K
+0.92%
Dec 31, 2024
Amundi Asset Management, SAS
4.71M
2.18%
-798.61K
-14.50%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
3.96M
1.83%
-111.67K
-2.74%
Dec 31, 2024
DWS Investments UK Limited
2.14M
0.99%
+712.11K
+50.02%
Dec 31, 2024
Swedbank Robur Fonder AB
2.03M
0.94%
-95.44K
-4.49%
Feb 28, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sex, 6 de jun
Atualizado em: sex, 6 de jun
Nome
Proporção
First Trust Nasdaq Lux Digi Health Solutions ETF
4.69%
Global X Genomics & Biotechnology ETF
3.96%
Invesco Biotechnology & Genome ETF
3.29%
ROBO Global Healthcare Technology & Innovation ETF
1.8%
Franklin Genomic Advancements ETF
1.75%
VanEck Biotech ETF
1.74%
iShares Health Innovation Active ETF
1.02%
Harbor Long-Short Equity ETF
0.9%
FlexShares US Quality Low Volatility Index Fund
0.85%
WisdomTree US AI Enhanced Value Fund
0.79%
Ver Mais
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporção4.69%
Global X Genomics & Biotechnology ETF
Proporção3.96%
Invesco Biotechnology & Genome ETF
Proporção3.29%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.8%
Franklin Genomic Advancements ETF
Proporção1.75%
VanEck Biotech ETF
Proporção1.74%
iShares Health Innovation Active ETF
Proporção1.02%
Harbor Long-Short Equity ETF
Proporção0.9%
FlexShares US Quality Low Volatility Index Fund
Proporção0.85%
WisdomTree US AI Enhanced Value Fund
Proporção0.79%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Data
Tipo
Proporção
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 17, 2025
Merger
36<35
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
Jan 18, 2024
Merger
25<24.25
